Evaluation of the Safety, Tolerability, and Pharmacokinetics of FE 999301 in Healthy Subjects with Inflammatory Gastrointestinal Disease

The primary objective of this study is to evaluate the **safety** and **tolerability** of FE 999301 in healthy subjects following both single and multiple doses. This is clinically relevant as it helps to determine the potential adverse effects and overall acceptability of the drug, which is crucial for its future application in treating conditions such as **inflammatory gastrointestinal disease**. The study also aims to assess the concentrations of FE 999301 in the body, which is important for understanding its pharmacokinetics and optimizing dosing regimens.

The clinical trial focuses on **Inflammatory Gastrointestinal Disease** and involves a study population exclusively composed of male participants. The age range of the participants falls within the category code "3," which typically corresponds to adults aged 18 to 65 years. The trial does not include a vulnerable population, and the selection criteria for the trial population have not been specified by the sponsor. Additionally, the sponsor has not provided information regarding the total number of participants. The study does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The absence of detailed inclusion or exclusion criteria suggests a broad approach to participant selection, although specific criteria may exist but are not disclosed in the available data.

The clinical trial is designed to evaluate the **safety** and tolerability of FE 999301 in healthy subjects following single and multiple doses. This Phase 1 trial will focus on individuals without any underlying health conditions, specifically excluding those with **inflammatory gastrointestinal disease**. The trial is structured as a randomized, double-blind, and controlled study to ensure unbiased results and reliable data collection. The estimated recruitment start date is February 19, 2024, with the trial expected to conclude by October 12, 2024.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status, collect data on drug concentrations, and assess any adverse effects. The end-of-study visit will mark the completion of the trial for each participant, where final assessments will be conducted to gather comprehensive data on the drug's impact.

The expected duration of participant involvement will vary depending on the dosing schedule but will generally align with the overall trial timeline. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or withdraw consent. The trial's design and procedures are meticulously crafted to ensure the collection of high-quality data while prioritizing participant safety and adherence to ethical standards.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is February 19, 2024, with an anticipated end date of October 12, 2024. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include measuring changes in relevant biomarkers or initial symptom improvement, depending on the investigational product and the condition being studied. Data collection and analysis are expected to follow standard clinical trial protocols, utilizing validated tools and instruments appropriate for the investigational context. The trial's design and methodology will adhere to regulatory standards to ensure the reliability and validity of the efficacy data collected.